New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Application based on results from the TROPION-Breast01 Phase III trial
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Combination shows consistent benefit across prespecified post-progression outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Subscribe To Our Newsletter & Stay Updated
